Dec 12, 2022 4:05pm EST Inhibikase Therapeutics Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro
Dec 07, 2022 4:05pm EST Inhibikase Therapeutics Provides Update to FDA Clinical Hold of IkT-148009 Programs
Nov 22, 2022 8:00am EST Inhibikase Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference
Nov 14, 2022 5:45pm EST Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity
Nov 08, 2022 8:00am EST Inhibikase Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022
Oct 12, 2022 8:00am EDT Inhibikase Therapeutics to Present at the Cambridge Healthtech Institute's Inaugural Neurodegeneration Targets Conference
Sep 21, 2022 4:05pm EDT Inhibikase Therapeutics to Present at the Grand Challenges in Parkinson's Disease Conference
Sep 15, 2022 8:00am EDT Inhibikase Therapeutics to Present Data from Phase 1/1b study of IkT-148009 at the Movement Disorders Society Congress
Sep 08, 2022 8:30am EDT Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders